Skip to main content

Technology Overview

Metronomic Marvel

A Significant Leap Forward: SINNAIS™ the first AI driven smart implantable pump

The SINNAIS™ implantable smart pump device combines a fully implantable programable pump capable of metronomic,  delivery of microliter quantities of a therapeutic, a single lumen intraventricular catheter, and a microprocessor for controlling the pump and communicating wirelessly with external devices. It is a companion device for delivery of chemotherapeutic agents and other therapeutics (small and large molecules) directly to the brain and eventually to other organs and sites in the body.

Sinnais IPB-05-MTX

Unveiling Cutting-Edge Advancements

SINNAIS sets a new standard in controlled therapeutic drug delivery, outclassing other implantable pumps with its multiple advantages over current market offerings and those in development.

SINNAIS Implantable Pump Graphic

Local Delivery
SINNAIS is expected to be the first approved implantable pump for intraventricular or direct delivery to the brain ventricle, which reduces toxicity and ensures a more optimal dosage.
Metronomic Delivery
SINNAIS offers metronomic drug delivery, a departure from the standard intraventricular approach of single bolus doses at long intervals. Using an advanced piezoelectric pump, it ensures precise sub-microliter-level drug amounts delivered consistently in a programmed regimen.
Intraventricular Delivery
SINNAIS is set to become the first FDA-approved pump capable of delivering drugs directly into the brain (CSF). Currently, FDA-approved drug delivery methods include systemic delivery, intrathecal delivery, and the use of the Ommaya reservoir, a funnel-shaped plastic device that requires surgical implantation into the brain on a temporary basis.
Flushing Mechanism
The catheter of SINNAIS incorporates a port that enables the physician to flush the catheter with saline to keep minerals, salts and crystalline deposits from building up and blocking the eye of the catheter. This is a common problem with existing drug pumps, and often requires surgery to remove and replace a clogged catheter.
Inlet Safety Valve
The inlet safety valve in SINNAIS prevents over infusion risks by blocking excess drug flow from the pump to the patient's body, addressing a hazard observed in other pumps, which has led to adverse effects and fatalities.
Wireless monitoring and programming; MRI-compatibility
An inlet safety valve in SINNAIS prevents excess drug flow into the patient's body, mitigating the risk of over infusion, a dangerous issue observed in some existing pumps, leading to adverse effects and fatalities.

SINNAIS™ Innovation Pipeline

With its embedded programmable parameters, including dose, time, sensory outputs, and closed-loop controls, SINNAIS™ architecture offers the flexibility to incorporate additional features in the future.

Despite efforts to individualize dosages, toxicity and efficacy outcomes of chemotherapy vary considerably among patients due to the highly variable and unpredictable biochemistry of the individual. The next generation of SINNAIS under development is expected to incorporate an on-board sensor that will monitor the concentrations of the delivered therapeutic in the cerebrospinal fluid (“CSF”) as well as other parameters, such as CSF pressure, that can be relevant to the management of patient therapy. The device is expected to be able to modify its delivery rate accordingly, or communicate the data to clinicians and enable them to make appropriate changes to the delivery rate of the pump in real time for individual patients.

An inductive charging unit that would provide patients with the ability to charge SINNAIS overnight by simply placing the charger over their skin, directly above the device is under development. Inductive charging will enable prolonged usage and will be necessary if we decide to pursue development of SINNAIS for treating conditions that have longer life expectancy.

There are plans to develop two proprietary catheters, one tailored for LC and the other designed for the treatment of brain tumors. These catheters are expected to have three lumens: the first will facilitate drug delivery to the desired locations, the second will transmit power from the pump’s internal battery to the catheter’s tip, connecting it to a sensor, and the third will flush the catheter’s tip to unclog blockages.

Involves the implantation of a catheter in or near the patient’s brain, an implantable pump for transporting CSF containing diseased cells or biomolecules associated with the neurological disease, and an implantable separation device for removing these cells or biomolecules. These elements would work together, with a magnetically-tagged antibody aiding in the removal of circulating diseased cells or biomolecules from the CSF.

SINNAIS Future Possibilities

SINNAIS incorporates an onboard microprocessor and wireless communication capabilities that allow the device to transmit patient data to the cloud for further evaluation by healthcare professionals and hospitals. Utilizing sophisticated AI algorithms.. To ensure the security and authentication of a large number of patients within our healthcare ecosystem, SINNAIS employs blockchain software.

Involves the implantation of a catheter in or near the patient’s brain, an implantable pump for transporting CSF containing diseased cells or biomolecules associated with the neurological disease, and an implantable separation device for removing these cells or biomolecules. These elements would work together, with a magnetically-tagged antibody aiding in the removal of circulating diseased cells or biomolecules from the CSF.

Involves the implantation of a catheter in or near the patient’s brain, an implantable pump for transporting CSF containing diseased cells or biomolecules associated with the neurological disease, and an implantable separation device for removing these cells or biomolecules. These elements would work together, with a magnetically-tagged antibody aiding in the removal of circulating diseased cells or biomolecules from the CSF.

Involves the implantation of a catheter in or near the patient’s brain, an implantable pump for transporting CSF containing diseased cells or biomolecules associated with the neurological disease, and an implantable separation device for removing these cells or biomolecules. These elements would work together, with a magnetically-tagged antibody aiding in the removal of circulating diseased cells or biomolecules from the CSF.